![]() |
|
Abstract Links |
|
Sprague RS, Stephenson AH, Ellsworth ML, Keller C, Lonigro AJ. Impaired release of ATP from red blood cells of humans with primary pulmonary hypertension. Exp Biol Med (Maywood). 2001;May;226(5):434-439. Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, Missouri. Previously, we reported that in the isolated perfused rabbit lung, red blood cells (RBCs) obtained from either rabbits or healthy humans were a required component of the perfusate to unmask evidence of nitric oxide (NO) participation in regulation of the pulmonary circulation. In addition, we found that mechanical deformation of rabbit and healthy human RBCs released ATP, a known agonist for enhanced NO synthesis. In contrast, RBCs obtained from patients with cystic fibrosis (CF) did not release ATP in response to mechanical deformation. The coexistence of airway disease and alveolar hypoxia in patients with CF precluded the drawing of conclusions relating a defect in RBC ATP release with the pulmonary hypertension associated with CF. Airway disease and alveolar hypoxia are not, however, features of primary pulmonary hypertension (PPH), a human condition of unknown etiology. We postulated that a defect in NO generation might contribute to the increased pulmonary vascular resistance in PPH, and as a first step, we hypothesized that RBCs obtained from patients with PPH would not release ATP. In contrast to RBCs of healthy humans, when RBCs of PPH patients were passed through filters (average pore size 12, 8, or 5 microm), ATP was not released and the RBCs exhibited reduced deformability. Moreover, when incubated with the active cAMP analogue, Sp-cAMP (100 microM), an activator of the CF transmembrane conductance regulator, ATP was not released. These results demonstrate that RBCs obtained from patients with PPH fail to release ATP whether the stimulus is mechanical or pharmacological. Thus, failure of RBCs to release ATP in patients with PPH might be a major pathogenetic factor that accounts for the heretofore unknown etiology of their pulmonary hypertension. 2006 TSI Health Sciences. Specifications | Research | Licensing | Where
to Buy | About
TSI | Contact
|
A Prospective, Randomized, Double Blind Study to Evaluate the Effects of Orally... A randomized, double-blind, placebo controlled triphosphate... Adenosine and cardioprotection in the diseased heart... Adenosine-mediated cardioprotection in the aging myocardium... Antihypertensive effect of all-cis-5,8,11,14,17... ATP flux through creatine kinase in the normal, stressed... ATP stimulates glucose transport through activation of P2... Beneficial effects of adenosine triphosphate on nutritional... Cardiovascular and pulmonary response to oral administration... Circulating ATP-induced vasodilatation overrides sympathetic... Clinical observation of oral adenosine triposthate in treating.... Diabetes mellitus and subjects' ageing: a study on the ATP... Effect of adenosine triphosphate and some derivatives on... Erythrocyte and the regulation of human skeletal muscle... Exogenous magnesium chloride-adenosine triphosphate... Impaired release of ATP from red blood cells of humans... Interstitial ATP and norepinephrine concentrations in... Intracoronary administration of adenosine triphosphate... Lung epithelial cells release ATP during ozone exposure... Measuring the contribution of pharmacological treatment... Mechanism of vasodilation to adenosine in coronary... Oxidative capacity and ageing in human muscle. Pretreatment of human myocardium with adenosine... Randomized clinical trial adenosine 5'-triphosphate... Reconditioning with ischemia or adenosine protects... Red blood cell regulation of microvascular tone through... Signaling pathways involved in adenosine triphosphate... Systemic hypoxia elevates skeletal muscle interstitia... The erythrocyte as a regulator of vascular tone. The hypotensive effect of docosahexaenoic acid... The T-tubule membrane ATP-operated P2X4 recepto...
|